Literature DB >> 31076823

[Left atrial appendage closure in non-valvular atrial fibrillation].

K G Häusler1, U Landmesser2,3,4.   

Abstract

Atrial fibrillation is the most frequent cardiac arrhythmia worldwide, causing approximately 20% of all ischemic strokes. Therefore, oral anticoagulation is recommended in patients with atrial fibrillation with at least a moderate risk of stroke; however, there is a significant proportion of patients who cannot undergo long-term oral anticoagulation. As the left atrial appendage is of major relevance for atrial fibrillation-induced thrombus formation, catheter-based or surgical closure of the left atrial appendage appears to be a promising therapeutic option. Large registry studies including patients with catheter-based left atrial appendage closure have proven its effectiveness and a decreasing procedure-related complication rate. This review article summarizes the current knowledge and introduces major ongoing randomized studies, which will investigate the impact of left atrial appendage closure on stroke prevention. The authors hope that the results of the randomized CLOSURE AF trial, which is funded by the German Center for Cardiovascular Research e. V. and is now recruiting patients in Germany, will help to solve many of the currently prevalent clinical questions.

Entities:  

Keywords:  Anticoagulation; CLOSURE-AF study; Cardiac arrhythmia; Cardiac source of embolism; Stroke

Mesh:

Substances:

Year:  2019        PMID: 31076823     DOI: 10.1007/s00059-019-4812-9

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  28 in total

1.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

Authors:  Vivek Y Reddy; Horst Sievert; Jonathan Halperin; Shephal K Doshi; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Brian Whisenant; Saibal Kar; Vijay Swarup; Nicole Gordon; David Holmes
Journal:  JAMA       Date:  2014-11-19       Impact factor: 56.272

2.  Cardiogenic Stroke Despite Low CHA2 DS2 -VASc Score: Assessing Stroke risk by Left Atrial Appendage Anatomy (ASK LAA).

Authors:  Sotirios Nedios; Emmanuel Koutalas; Jelena Kornej; Sascha Rolf; Arash Arya; Philipp Sommer; Daniela Husser; Gerhard Hindricks; Andreas Bollmann
Journal:  J Cardiovasc Electrophysiol       Date:  2015-08-17

3.  [Atrial appendage occlusion in atrial fibrillation? Pro].

Authors:  K G Häusler; U Landmesser; M Endres
Journal:  Nervenarzt       Date:  2015-10       Impact factor: 1.214

4.  Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques.

Authors:  Martin W Bergmann; Ulf Landmesser
Journal:  EuroIntervention       Date:  2014-08       Impact factor: 6.534

5.  Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.

Authors:  Vivek Y Reddy; David Holmes; Shephal K Doshi; Petr Neuzil; Saibal Kar
Journal:  Circulation       Date:  2011-01-17       Impact factor: 29.690

6.  Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug.

Authors:  Apostolos Tzikas; Samera Shakir; Sameer Gafoor; Heyder Omran; Sergio Berti; Gennaro Santoro; Joelle Kefer; Ulf Landmesser; Jens Erik Nielsen-Kudsk; Ignacio Cruz-Gonzalez; Horst Sievert; Tobias Tichelbäcker; Prapa Kanagaratnam; Fabian Nietlispach; Adel Aminian; Friederike Kasch; Xavier Freixa; Paolo Danna; Marco Rezzaghi; Paul Vermeersch; Friederike Stock; Miroslava Stolcova; Marco Costa; Reda Ibrahim; Wolfgang Schillinger; Bernhard Meier; Jai-Wun Park
Journal:  EuroIntervention       Date:  2016-02       Impact factor: 6.534

7.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

8.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

9.  Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study.

Authors:  Luigi Di Biase; Pasquale Santangeli; Matteo Anselmino; Prasant Mohanty; Ilaria Salvetti; Sebastiano Gili; Rodney Horton; Javier E Sanchez; Rong Bai; Sanghamitra Mohanty; Agnes Pump; Mauricio Cereceda Brantes; G Joseph Gallinghouse; J David Burkhardt; Federico Cesarani; Marco Scaglione; Andrea Natale; Fiorenzo Gaita
Journal:  J Am Coll Cardiol       Date:  2012-08-07       Impact factor: 24.094

10.  Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.

Authors:  Lucas V A Boersma; Boris Schmidt; Timothy R Betts; Horst Sievert; Corrado Tamburino; Emmanuel Teiger; Evgeny Pokushalov; Stephan Kische; Thomas Schmitz; Kenneth M Stein; Martin W Bergmann
Journal:  Eur Heart J       Date:  2016-01-27       Impact factor: 29.983

View more
  1 in total

1.  A Detailed Study to Discover the Trade between Left Atrial Blood Flow, Expression of Calcium-Activated Potassium Channels and Valvular Atrial Fibrillation.

Authors:  Pin Shen; Misbahul Ferdous; Xiaoqi Wang; Guojian Li; Runwei Ma; Xiangbin Pan; Hongming Zhang; Guimin Zhang; Zhiling Luo; Lakshme Kottu; Jiang Lu; Yi Song; Lin Duo; Jianming Xia; Enze Yang; Xiang Cheng; Manning Li; Shaohui Jiang; Yi Sun
Journal:  Cells       Date:  2022-04-19       Impact factor: 7.666

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.